在急诊室治疗急性疼痛的苏泽特里金:一流的NaV1.8阻断剂
Jace C Bradshaw1, Laeben Lester1, David A Leon2
1Department of Emergency Medicine and Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA.
概括
苏泽特里金是一种新的非阿片类止痛药,可有效缓解急性疾病的疼痛,而无需呼吸系统抑郁或成的风险. 它的口服配方和有利的安全概况使其成为急诊部疼痛管理的有希望的选择.
科学领域:
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
- 紧急医疗 紧急医疗
背景情况:
- 苏泽丁是第一个选择性,口服生物可用抑制器的周围电压门的通道NaV1.8.8.
- NaV1.8对于感觉至关重要,但在中枢神经系统和心脏组织中缺席,这表明有针对性的止痛机制.
- 在2025年1月,suzetrigine成为20多年来FDA批准的第一个非阿片类止痛药.
研究的目的:
- 审查临床前数据,监管文件和苏泽特里金的2-3期随机对照试验.
- 描述其在急诊室 (ED) 疼痛管理中的潜在作用.
- 评估其有效性,安全性和作为阿片类药物节约性止痛药的潜力.
主要方法:
- 临床前研究,监管机构提交和发表的2-3期随机双盲试验的审查.
- 分析了三项涉及急性疼痛患者的第三阶段研究数据,主要是手术起源的.
- 评估疼痛评分,不良事件和滥用责任信号.
主要成果:
- 在3期试验中,苏泽丁与安慰剂相比,在48小时疼痛得分上显示出临床上有意义的减少.
- 止痛药被发现相当于可/乙氨基,可感知缓解从60分钟开始,在240分钟达到顶峰.
- 副作用是罕见和轻微的,没有滥用责任或呼吸道损害的信号;GFR的短暂下降自发地消失.
结论:
- 苏三因其选择性NaV1.8抑制而提供无呼吸抑郁,高兴感或心律失常风险的止痛.
- 它的口服配方,良好的安全性概况和缺乏成潜力与阿片类药物缓解疼痛的ED指南保持一致.
- 需要进一步的前性ED研究来确认在各种类型的疼痛中的有效性,评估成本效益,并评估长期使用.
相关概念视频
Depolarizing Blockers: Pharmocokinetics
672
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
672
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
691
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
691
Depolarizing Blockers: Mechanism of Action
3.2K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
3.2K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.1K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.1K
Analgesia and Pain Management
2.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.4K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.2K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.2K


